Real-World study tracks bleeding and daily life in rare bleeding disorder
NCT ID NCT06883240
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This study observes 44 people with type 3 von Willebrand disease, a rare bleeding disorder, who are already on standard preventive treatment. Researchers will track how often bleeding episodes occur and how the condition affects quality of life over at least 24 weeks. No new drug is being tested; the goal is to gather real-world information on current care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AOU Careggi
Florence, Tuscany, 50134, Italy
-
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, 2193, South Africa
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz
Duisburg, 47051, Germany
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Groupe Hospitalier Necker Enfants Malades
Paris, 75015, France
-
Hopital Claude Huriez - CHU Lille
Lille, 59037, France
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Hospital Universtiario Virgen del Rocio
Seville, 41013, Spain
-
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin
Frankfurt/M., 60590, Germany
-
IPS SURA Industriales Medellín
Medellín, Colombia
-
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
-
Instytut Hematologii i Transfuzjologii
Warsaw, 02-776, Poland
-
Kurume University Hospital
Fukuoka, 830-0011, Japan
-
Manchester Royal Infirmary
Manchester, M13 9WL, United Kingdom
-
McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
-
Sahlgrenska Universitetssjukhuset
Gothenburg, S-413 45, Sweden
-
St Thomas' Hospital
London, SE1 7EH, United Kingdom
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Tokyo Medical University Hospital
Tokyo, 160-0023, Japan
-
UC Davis
Sacramento, California, 95817, United States
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
Universita' Degli Studi La Sapienza-Ist.Di Ematologia
Rome, Lazio, 00161, Italy
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Minnesota Medical Center
Minneapolis, Minnesota, 55455, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could provide real-world data on how well current standard treatments control bleeding and affect daily life in type 3 VWD.
What could go wrong
This is an observational study, not a trial of a new treatment. It only collects existing data, so it cannot prove whether a new approach works or is safe.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.